Waldenström’s Macroglobulinemia
European Imbruvica approval for Janssen
July 20, 2015Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer
Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
